Funding for this research was provided by:
National Cancer Institute (R35CA210098)
Received: 12 March 2018
Accepted: 2 July 2018
First Online: 16 July 2018
Ethics approval and consent to participate
: Not applicable: this is not a research clinical trial, consent for use and publication of patient data was obtained as below.
: Patient consent was obtained and can be requested separately as per the submission guidelines.
: TFG has received research funding from Bristol-Myers Squibb, the manufacturer of ipilimumab and nivolumab.
: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.